MTVA
MetaVia Inc.
NASDAQ: MTVA · HEALTHCARE · BIOTECHNOLOGY
$1.44
-3.36% today
Updated 2026-04-30
Market cap
$8.21M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-7.35
Dividend yield
—
52W range
$1 – $19
Volume
0.1M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$19.33
+1242.36%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-4.86M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-13.97M | $-12.47M | $-27.59M | $-12.97M | $-1.93M |
| EPS | — | — | — | — | $-7.35 |
| Free cash flow | $-11.71M | $-10.85M | $-24.72M | $-15.70M | $-4.86M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
MetaVia Inc. trades at $1.44. Our Smart Value Score of 23/100 indicates the stock is weak.
Frequently asked questions
What is MetaVia Inc.'s stock price?
MetaVia Inc. (MTVA) trades at $1.44.
Is MetaVia Inc. overvalued?
Smart Value Score 23/100 (Grade F, Strong Sell).
What is the price target of MetaVia Inc. (MTVA)?
The analyst target price is $19.33, representing +1242.4% upside from the current price of $1.44.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-195.60%
Beta0.35
50D MA$1.46
200D MA$6.36
Shares out0.01B
Float0.00B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—